Prime Medicine Q3 2026 Results: Net Loss of $39M, Loss Narrows
Prime Medicine reported a net loss of $130.3 million for the nine months ended September 30, 2026, an improvement from the $155.1 million loss in the prior year period. Total revenue increased to $6.2 million, primarily driven by collaboration revenue from related parties, while total stockholders' equity significantly declined from $120.9 million to $8.4 million during the first nine months of 2026.
- Key figure
- Net loss $39M